Researchers at Columbia University College of Dental Medicine have developed an exosome-based platform, “safeEXO-Cas,” that significantly enhances the delivery of CRISPR/Cas9 genome editing components to specific cells and tissues.
CRISPR/Cas9 is a unique technology that enables geneticists and medical researchers to edit parts of the genome by removing, adding or altering sections of the DNA sequence. The study, published in Theranostics, demonstrates the potential of this innovative platform to revolutionize gene therapy and precision medicine.
The research, led by Dr...
Read More
Recent Comments